 Despite the COVID -19 pandemic, Collegium Pharmaceutical had an impressive 2020. The company recorded a full year of profitability and commercial progress. Collegium is off to a good start in 2021, with the company reporting Xtampza ERs quarter-to-date total script volume being up 13 over Q4. 